{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:27:35Z","timestamp":1784921255326,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:25:54Z","timestamp":1702578354000},"page":"744-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report of two adults with F508del\/3849+10\u00a0kb C &gt; T genotype regaining exocrine pancreatic function following treatment with elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6906-9901","authenticated-orcid":false,"given":"Nela","family":"Stastna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pokojova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2023.12.001_bib0001","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1365-2362.2001.00876.x","article-title":"Analysis of exocrine pancreatic function in cystic fibrosis: one mild CFTR mutation does not exclude pancreatic insufficiency","volume":"31","author":"Walkowiak","year":"2001","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.jcf.2023.12.001_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.jcf.2023.12.001_bib0003","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.gastro.2010.09.046","article-title":"Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis","volume":"140","author":"Ooi","year":"2011","journal-title":"Gastroenterology"},{"issue":"8970","key":"10.1016\/j.jcf.2023.12.001_bib0004","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0140-6736(95)92165-6","article-title":"3849+10 kb C\u2013>T mutation and disease severity in cystic fibrosis","volume":"346","author":"Stern","year":"1995","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.jcf.2023.12.001_bib0005","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1183\/09031936.05.10100004","article-title":"The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype","volume":"25","author":"Dugu\u00e9p\u00e9roux","year":"2005","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2023.12.001_bib0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"suppl 59","key":"10.1016\/j.jcf.2023.12.001_bib0007","article-title":"Phenotypic characteristics in adult cystic fibrosis (CF) patients carrying 3849+10kbC&gt;T mutation in Russia","volume":"46","author":"Krasovskiy","year":"2015","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jcf.2023.12.001_bib0008","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.12.001_bib0009","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.12.001_bib0010","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41395-018-0123-7","article-title":"Ivacaftor CFTR potentiator therapy is efficient for pancreatic manifestations in cystic fibrosis","volume":"113","author":"Kounis","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323017253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323017253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:09:02Z","timestamp":1783019342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323017253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199323017253"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.12.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case report of two adults with F508del\/3849+10\u00a0kb C > T genotype regaining exocrine pancreatic function following treatment with elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}